Core Insights - Guangdong Province is set to enhance its traditional Chinese medicine (TCM) sector in 2026, focusing on nine key areas including digital empowerment and standardization of TCM practices [1][2] Group 1: Key Initiatives - The province will deepen comprehensive reforms in TCM and promote the establishment of a national TCM comprehensive reform demonstration zone [1] - Guangdong aims to improve TCM service capabilities through the implementation of healthcare strengthening projects [1] - A significant focus will be on integrating Western and Chinese medicine, establishing a long-term collaborative mechanism for clinical projects addressing major diseases [1] Group 2: Talent Development and Research - Guangdong plans to strengthen its TCM research and innovation framework, accelerating the transformation of research outcomes [2] - The province will initiate the selection of national TCM masters and renowned practitioners, fostering leadership and high-level talent in the TCM field [2] - A multi-tiered talent development system will be established to enhance the quality of TCM professionals [2] Group 3: Industry and Cultural Promotion - The province will promote high-quality development across the entire TCM industry chain, focusing on resource protection and source management [2] - Efforts will be made to expand the cultural influence of TCM and accelerate its international outreach [2] - The establishment of a traceability system for key TCM materials from the Lingnan region will be prioritized [2]

Core Viewpoint - A significant number of traditional Chinese medicine (TCM) products are at risk of being eliminated from the market due to new regulatory requirements that will take effect in July 2026, which mandate clearer safety information in product descriptions [3][10]. Industry Overview - The new regulations, effective from July 2023, require that any TCM product with unclear safety information (labeled as "unclear") will not be eligible for re-registration after July 1, 2026 [3][10]. - Approximately 75% of TCM products currently on the market have safety information marked as "unclear," which poses a substantial risk of elimination for these products [5][10]. Market Impact - The impending regulatory changes are expected to lead to a significant reshuffling of market shares within the TCM industry, as many companies may not be able to meet the new requirements [10][11]. - Notable products facing potential withdrawal include those with substantial sales figures, such as Longmu Bone Strengthening Granules, which is projected to exceed 1 billion yuan in retail sales in 2024 but has unclear safety information [7][10]. Regulatory Context - The regulatory changes aim to enhance the quality of TCM products rather than a blanket elimination of all products, allowing companies to submit additional research and safety reports to comply [10][12]. - The policy encourages companies to invest in research and development to clarify the efficacy and safety of their products, thereby improving the overall scientific standards of TCM [12][13]. Future Developments - Many leading TCM companies have already begun to prepare for compliance with the new regulations, with some having successfully updated their product safety information [14]. - The regulatory framework is expected to foster a more competitive environment, potentially benefiting companies that can adapt and innovate while disadvantaging those that cannot meet the new standards [11][12].

中医药高质量发展，离不开壮大中医药新质生产力和建设高水平中医药人才队伍。广东将建强中医药科 研创新矩阵，加快科研成果转化，强化数智赋能，推进中医药标准化，建设中医药标准化研究转化中 心，推动粤港澳大湾区规则衔接机制对接，进一步开展中医湾区标准的制定实施和推广应用；今年，广 东将开展新一届国医大师、全国名中医遴选推荐工作，推进中医药领军人才、青年拔尖人才和高水平创 新团队等人才培养项目，健全中医药行业表彰奖励长效机制，分类打造多层次人才队伍。 广东还将统筹推进中医药产业和事业发展，加强源头管控与资源保护，促进全产业链高质量发展，做强 院内制剂产业，推进岭南双"八味"中药材保护，推动构建覆盖广陈皮、化橘红等岭南中药材保护主要品 种的全过程追溯体系；扩大中医药文化影响力，加快中医药"走出去"步伐；并将加强医德医风建设，抓 好安全生产稳定。 具体而言，广东将深化中医药综合改革，全面推进国家中医药综合改革示范区建设，推广三明医改促进 中医药传承创新发展的经验做法，实施好第一批、第二批中医药传承创新发展示范项目；提升中医药服 务能力，实施好医疗卫生强基工程中医药行动，持续推动优质医疗资源提质下沉。 促进中西医结合是一大工 ...

Core Viewpoint - The official release of the ISO international standard for "Broken Wall Ganoderma Spore Powder" marks a significant step in the internationalization and standardization of traditional Chinese medicine (TCM), providing a unified framework for the global industry [5][7]. Group 1: Standard Release and Significance - The ISO international standard (ISO/TS 25006:2025) for "Broken Wall Ganoderma Spore Powder" was officially released during a seminar focused on the high-quality international development of TCM [5]. - This standard establishes a comprehensive standardization system for the global broken wall Ganoderma spore powder industry, covering aspects from raw materials to production processes and quality control [7]. - The standard sets a minimum requirement of ≥95% wall-breaking rate and introduces a multi-index evaluation system for active components, ensuring both traditional practices and modern technology are integrated [7]. Group 2: Impact on Consumers and Industry - For consumers, the standard provides a more reliable product guarantee, enabling better assessment of product safety and effectiveness, and helping to distinguish genuine products from counterfeits [7]. - The company, Shouxiangu, has been a key player in TCM standardization, having led or participated in the formulation of over 100 TCM standards, including 8 international standards [7][8]. Group 3: Future Directions and Challenges - The standardization initiative is expected to drive the internationalization of TCM, with a focus on quality and safety, while also addressing the unique challenges posed by the traditional practices of TCM [9][10]. - Experts emphasize the need for a balance between standardization and the unique characteristics of TCM, advocating for a system that integrates traditional wisdom with modern scientific approaches [10][11]. - The seminar highlighted the importance of protecting authentic medicinal materials and educating international markets as key factors in promoting the internationalization of TCM [11].

Core Viewpoint - The official release of the ISO international standard for "Broken Wall Ganoderma Spore Powder" marks a significant step towards the internationalization of traditional Chinese medicine (TCM), providing a unified framework for quality and safety in the global market [4][6]. Group 1: Standard Release and Significance - The ISO standard (ISO/TS 25006:2025) for Broken Wall Ganoderma Spore Powder was officially released, establishing a comprehensive standardization system from raw materials to production and testing [4][5]. - This standard serves as a "world language" for TCM, facilitating the internationalization of Zhejiang-produced traditional medicine [4][6]. Group 2: Production and Quality Control - The standard specifies raw material sourcing requirements and sets a critical parameter of ≥95% wall-breaking rate, ensuring standardized production control [5]. - It introduces a fingerprinting multi-index evaluation system for active components, balancing traditional practices with modern technology [6]. Group 3: Consumer Impact and Industry Leadership - For consumers, the standard enhances product reliability, enabling better assessment of safety and efficacy, and helping to distinguish quality products [6]. - The company, Shouxiangu, has led the development of over 100 TCM standards, including 8 international standards, contributing to the global recognition of TCM [6][7]. Group 4: Challenges and Innovations in TCM - The implementation of the standard addresses a global quality gap in TCM and injects new momentum into the internationalization of the industry [7]. - Experts emphasize the need for a balance between traditional TCM practices and modern standardization requirements, highlighting the challenges posed by differing legal and cultural contexts [7][8]. Group 5: Future Directions - The company aims to continue its efforts in international standard formulation, promoting more Zhejiang-produced medicinal materials globally and enhancing cooperation with countries along the "Belt and Road" initiative [6][8]. - The conference signifies a new phase in TCM internationalization, focusing on standard leadership, industry collaboration, and global sharing [8].

Core Viewpoint - The release of the ISO international standard for "Broken Wall Ganoderma Spore Powder" marks a significant advancement in the standardization of traditional Chinese medicine (TCM), promoting quality and international development in the industry [1][2][4]. Group 1: Standardization and Innovation - The ISO standard (ISO/TS 25006:2025) for "Broken Wall Ganoderma Spore Powder" will be implemented in July 2025, following previous standards for other TCM products [2]. - The standard establishes key parameters such as raw material sources, a minimum 95% breaking rate, and a multi-index quality control system, enhancing production technology standardization [4]. - Experts emphasize that TCM standardization is a process of deriving scientific rules from clinical practices to form internationally recognized standards [4]. Group 2: Economic Impact - The implementation of ISO standards has led to significant increases in international trade, with related products seeing trade growth of 284.5% and 37.5% for Ganoderma and Dendrobium, respectively [5]. - The standards have been adopted in 31 countries, including major markets like the US, Canada, Australia, and Germany, facilitating trade recognition [5]. Group 3: International Collaboration - Collaborations with international institutions, such as clinical research on TCM's anti-tumor effects and cardiovascular benefits, are enhancing the scientific basis for standardization [6]. - The Zhejiang provincial government plans to strengthen the internationalization of TCM standards, focusing on local medicinal materials and specialty TCM products [6]. Group 4: Future Directions - The establishment of a comprehensive standard system covering the entire industry chain, from cultivation to clinical evaluation, is seen as essential for enhancing the industry's competitiveness [7]. - The company aims to deepen international standard formulation and promote local medicinal materials globally, particularly in countries along the Belt and Road Initiative [9].

新华社北京1月24日电 （记者 田晓航）"十四五"时期，中医国家标准数量大幅增长，覆盖范围持续拓 展，国际化迈出关键步伐。 （来源：内蒙古日报） 转自：内蒙古日报 作为中医药领域的全国标准化技术委员会之一，全国中医标准化技术委员会由国家中医药管理局筹建并 进行业务指导，主要负责提出中医标准化工作方针、政策和技术措施的建议，组织制定中医标准体系 表，中医国家标准的制定、修订、审查、发布、宣贯、推广等工作。 "十四五"时期，全国中医标准化技术委员会制定并完善中医国家标准体系表，构建覆盖中医临床、中医 基础、少数民族医药、中医药信息等方向的标准体系框架，明确标准优先级与布局方向，并开展中医临 床专科标准体系研究试点；累计推动19项国家标准外文版立项，覆盖中医四诊技术操作、临床名词术语 等方面的重要标准。 标准是中医药事业发展的重要技术支撑。记者1月24日从全国中医标准化技术委员会2025年年会了解 到，"十四五"时期，全国中医标准化技术委员会累计推进发布中医国家标准34项，数量占同时期发布的 中医药国家标准的65.4%。目前，中医国家标准数量达到36项。 ...

Group 1 - The core viewpoint of the articles highlights Hong Kong's efforts to establish a robust framework for Traditional Chinese Medicine (TCM) to enhance its global presence and acceptance [1][2][3] Group 2 - Hong Kong has developed a regulatory system for TCM, including the establishment of the Hong Kong Chinese Medicine Standards and a Chinese Medicine Testing Center, which will begin phased operations in December 2025 [1] - The Hong Kong government has invested a total of 1 billion HKD in the Chinese Medicine Development Fund since 2019, supporting over 10 funding programs in training, research, public awareness, industry development, and quality enhancement [2] - As of November 2025, there are 10,842 registered Chinese medicine practitioners in Hong Kong, with over 90% practicing in the community, creating a strong grassroots healthcare network [2] Group 3 - The Hong Kong Chinese Medicine Hospital, set to begin phased services in December 2025, aims to promote TCM education, training, and research innovation, supporting clinical research and the development of Chinese patent medicines [2] - The TCM industry in Hong Kong actively organizes promotional activities, with government support for projects that enhance public understanding and recognition of TCM [2][3]

Core Viewpoint - The National Healthcare Security Administration has revised the coding rules for traditional Chinese medicine (TCM) decoction pieces, introducing new identifiers to enhance traceability and transparency in the industry [1]. Group 1: Coding Revisions - The revision does not significantly alter the existing coding structure but adds two key segments: the "Authentic Medicinal Material Identifier" and the "Decoction Piece Enterprise Code" [1]. - The "Authentic Medicinal Material Identifier" serves as a geographical certification label for decoction pieces, making information about authentic varieties like Yunnan Sanqi and Sichuan Chuanbei clear [1]. - The "Decoction Piece Enterprise Code" accurately links to the producing enterprises, ensuring traceability and accountability [1]. Group 2: Industry Impact - The new coding segments fill a long-standing information gap regarding the authenticity and production of decoction pieces, thereby enhancing product transparency [1]. - The coding provides each decoction piece with a unique healthcare "identity," applicable in billing, reimbursement audits, and fund supervision, which helps enforce corporate responsibility [1]. - The current database includes over ten thousand decoction piece codes, covering more than 3,000 types of medicinal materials and 22 categories of efficacy, achieving a "national unified code" [1].

Core Viewpoint - The 22nd China International Health Expo highlighted the achievements of Zhejiang Shouxiangu Pharmaceutical Co., Ltd., recognized as a leading enterprise in the health industry, showcasing its innovations in the Ganoderma lucidum sector and its commitment to traditional Chinese medicine and technological advancement [2][5]. Group 1: Company Achievements - Shouxiangu has established the world's largest Ganoderma lucidum germplasm resource bank, preserving over 13,388 varieties since the 1990s [3]. - The company developed the first domestically approved Ganoderma lucidum variety "XianZhi No. 1" in 2001, breaking the reliance on imports from Japan and South Korea [3]. - Shouxiangu has built over 10,000 acres of organic medicinal herb cultivation bases, achieving various organic certifications from China, the EU, the US, Japan, and Canada [3]. Group 2: Technological Innovations - The company has independently developed the third-generation wall-breaking technology for Ganoderma lucidum spore powder, significantly enhancing the effective ingredient content by over 10 times and improving absorption rates by an average of 29 times compared to regular wall-breaking spore powder [3]. - Shouxiangu has been recognized with a gold medal at the 46th Geneva International Exhibition of Inventions for its technological breakthroughs [3]. Group 3: Standardization and Digital Transformation - Since 2006, Shouxiangu has undertaken the development of over 100 international, national, and industry standards, including ISO standards for Ganoderma lucidum and other medicinal herbs [4]. - The company is set to implement new ISO standards for "White Atractylodes" and "Wall-Breaking Ganoderma lucidum spore powder" in July 2024 and July 2025, respectively, enhancing China's international influence in traditional medicine [4]. - Shouxiangu is advancing digital transformation by creating a collaborative application system across the entire industry chain, including smart farms and factories, which has led to a 50%-80% increase in medicinal herb yield and a 35% improvement in effective ingredient stability [4]. Group 4: Product Offerings and Cultural Heritage - At the expo, Shouxiangu showcased its core product lines, including Ganoderma lucidum, Dendrobium, and saffron, covering traditional Chinese medicine products, health foods, and herbal daily necessities [5]. - The company also presented its national intangible cultural heritage techniques for traditional Chinese medicine processing, emphasizing its commitment to cultural preservation alongside technological innovation [5].